It's more than a coincidence that cardiology companies Boston Scientific Corp. and now Guidant Corp. have recently invested in start-ups developing new devices for the treatment of lung diseases. In April, Boston Scientific invested in Broncus Technologies Inc. and just last week, Guidant's venture arm, Compass, invested in Spiration Inc. Interventional pulmonology today, it seems, reminds the large companies of the old days in interventional cardiology, and they hope the new field will grow as rapidly.
In some ways, diseases of the heart and lungs, and the procedure-oriented practitioners who address them, are similar. As in heart disease, emphysema, lung cancer, and even asthma result in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?